Lung and stomach cancer waits jump 12–14 days, raising progression risk

For biopharma and clinical development teams, every added day between diagnosis and first treatment is a window for early-stage tumors to progress — and a variable that can confound neoadjuvant and perioperative trial endpoints. The JAMA Surgery cohort shows that window widened across all six studied tumor types, creating both a risk to trial integrity and an opening for urgency-stratifying diagnostics.

Median wait times between a cancer diagnosis and the start of treatment grew by more than 10 days — nearly two weeks — in the United States between 2012 and 2023, according to a study published in JAMA Surgery and reported on August 18, 2026 by Fox News affiliates. Researchers from the University of California, Los Angeles and Massachusetts General Hospital analyzed national data on more than two million patients diagnosed between January 2012 and December 2023, focusing on adults with early to locally advanced breast, colon, lung, pancreatic, stomach, and esophageal cancers who received surgery as part of their initial care. The investigators measured time from diagnosis to first treatment, whether surgery or pre-surgical (neoadjuvant) therapy.

“

The JAMA Surgery cohort shows that window widened across all six studied tumor types, creating both a risk to trial integrity and an opening for urgency-stratifying diagnostics.

The magnitude of the increase varied by tumor type but was uniformly in the wrong direction. Stomach cancer patients experienced the largest absolute rise, from a median of 35 days to 49 days, followed closely by lung cancer, which climbed from 41 days to 53 days. Esophageal cancer waits rose from 38 to 48 days, breast cancer from 34 to 45, pancreatic from 23 to 32, and colon from 20 to 31. Perhaps most troubling, the researchers found that a growing proportion of patients waited 60 days or longer before beginning treatment, and the pattern was not confined to overstretched community hospitals; delays were also documented at high-volume academic medical centers. Dr. Marc Siegel, Fox News senior medical analyst, who was not involved in the research, characterized the findings bluntly: "This is part of our healthcare system that needs fixing immediately."

The context for these numbers matters. The study deliberately restricted its cohort to early- and locally-advanced disease treated with surgery as part of initial care — the very patients for whom timely intervention is most likely to be curative and for whom delay carries the clearest risk of tumor progression and upstaging. A diagnosis-to-treatment interval that grows from roughly three to seven-plus weeks across a decade signals structural friction rather than a single cause: it implicates preoperative imaging and biopsy scheduling, pathology turnaround, operating-room capacity, anesthesia and surgical staffing shortages, prior-authorization and insurance navigation delays, and post-pandemic surgical backlogs that never fully cleared. That academic medical centers are not immune undermines the assumption that regionalization or referral to centers of excellence is a sufficient answer to access problems.

For health-system operators and health IT vendors, the study functions as a demand signal. Ten-plus days of added latency across millions of episodes represents measurable avoidable cost, worse patient experience, and — for early-stage disease — potentially worse clinical outcomes. The finding that a growing share of patients now cross the 60-day threshold is a red flag that existing navigation, scheduling, and care-coordination infrastructure is not scaling with volume or complexity. Health systems that can compress diagnosis-to-treatment intervals through centralized intake, automated prior authorization, AI-assisted triage, and real-time capacity visibility stand to differentiate themselves on a metric that payers, referring physicians, and patients increasingly scrutinize.